CSIMarket
 


Eiger Biopharmaceuticals Inc   (EIGR)
Other Ticker:  
 

Eiger Biopharmaceuticals Inc 's Working Capital Ratio

EIGR's quarterly Working Capital Ratio and Current Assets, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the third quarter 2023, Working Capital Ratio deteriorated to 3.35 a new company low.

Within Biotechnology & Pharmaceuticals industry 115 other companies have achieved higher Working Capital Ratio than Eiger Biopharmaceuticals Inc in third quarter 2023. While Working Capital Ratio total ranking in the third quarter 2023 has deteriorated compared to the prior quarter from 1075 to 1421.

Explain Working Capital Ratio
How much in Current Assets EIGR´s has?
What is the value of EIGR´s Current Liabilities?


EIGR Working Capital Ratio (Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities Change -36.85 % -23.44 % -34.58 % -15.86 % 20.73 %
Y / Y Current Assets Change -61.61 % -55.31 % -34.23 % 13.71 % 43.6 %
Working Capital Ratio MRQ 3.35 4.3 4.11 4.77 5.51
EIGR's Total Ranking # 1421 # 1075 # 1126 # 719 # 1077
Seq. Current Liabilities Change -0.45 % -30.44 % -4.33 % -4.69 % 20.69 %
Seq. Current Assets Change -22.5 % -27.27 % -17.55 % -17.4 % -9.77 %



Working Capital Ratio third quarter 2023 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 116
Healthcare Sector # 574
Overall Market # 1421


Working Capital Ratio Statistics
High Average Low
33.19 9.55 3.35
(Mar 31 2014)   (Sep 30 2023)




Financial Statements
Eiger Biopharmaceuticals Inc 's Current Liabilities $ 16 Millions Visit EIGR's Balance sheet
Eiger Biopharmaceuticals Inc 's Current Assets $ 55 Millions Visit EIGR's Balance sheet
Source of EIGR's Sales Visit EIGR's Sales by Geography


Cumulative Eiger Biopharmaceuticals Inc 's Working Capital Ratio

EIGR's Working Capital Ratio for the trailling 12 Months

EIGR Working Capital Ratio

(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities TTM Growth -36.85 % -23.44 % -34.58 % -15.86 % 20.73 %
Y / Y Current Assets TTM Growth -61.61 % -55.31 % -34.23 % 13.71 % 43.6 %
Working Capital Ratio TTM 4.2 4.72 5.39 5.24 4.89
Total Ranking TTM # 3670 # 4026 # 3457 # 2283 # 645
Seq. Current Liabilities TTM Growth -0.45 % -30.44 % -4.33 % -4.69 % 20.69 %
Seq. Current Assets TTM Growth -22.5 % -27.27 % -17.55 % -17.4 % -9.77 %


On the trailing twelve months basis In spite of the year on year decrease in EIGR's Current Liabilities to $16.32 millions, cumulative Working Capital Ratio to 4.2 below the EIGR average Working Capital Ratio.
Working Capital Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 160 other companies have achieved higher Working Capital Ratio than Eiger Biopharmaceuticals Inc . While Working Capital Ratio overall ranking has improved so far to 3670, from total ranking during the twelve months ending second quarter 2023 at 4026.

Explain Working Capital Ratio
How much in Current Assets EIGR´s has?
What is the value of EIGR´s Current Liabilities?

TTM Working Capital Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 161
Healthcare Sector # 976
Within the Market # 3670


trailing twelve months Working Capital Ratio Statistics
High Average Low
8.51 6.28 4.12
(Sep 30 2019)   (Sep 30 2023)




Companies with similar Working Capital Ratio in the quarter ending Sep 30 2023, within Biotechnology & Pharmaceuticals Industry Working Capital RatioSep 30 2023 MRQ Current AssetsSep 30 2023 MRQ Current Liabilities
Turnstone Biologics Corp   9.08 $ 118.835  Millions$ 13.081  Millions
Jasper Therapeutics Inc   8.84 $ 105.218  Millions$ 11.906  Millions
Fate Therapeutics Inc   8.81 $ 364.174  Millions$ 41.333  Millions
Springworks Therapeutics Inc   8.60 $ 432.383  Millions$ 50.283  Millions
Century Therapeutics inc   8.50 $ 173.703  Millions$ 20.435  Millions
Atyr Pharma Inc   8.33 $ 107.298  Millions$ 12.881  Millions
Pluri Inc   8.16 $ 35.258  Millions$ 4.322  Millions
Monte Rosa Therapeutics Inc   8.09 $ 182.911  Millions$ 22.609  Millions
Senti Biosciences Inc   7.81 $ 79.007  Millions$ 10.114  Millions
Tracon Pharmaceuticals Inc   7.72 $ 8.340  Millions$ 1.080  Millions
Halozyme Therapeutics Inc   7.63 $ 879.006  Millions$ 115.185  Millions
Tscan Therapeutics Inc   7.56 $ 217.567  Millions$ 28.775  Millions
C4 Therapeutics Inc   7.39 $ 223.686  Millions$ 30.271  Millions
Immunovant Inc   7.34 $ 291.177  Millions$ 39.645  Millions
Surrozen Inc   7.25 $ 48.357  Millions$ 6.672  Millions
Palisade Bio Inc   7.16 $ 16.266  Millions$ 2.273  Millions
Passage Bio inc   6.85 $ 135.711  Millions$ 19.811  Millions
Humacyte Inc   6.79 $ 102.851  Millions$ 15.137  Millions
Ginkgo Bioworks Holdings Inc   6.78 $ 1,141.846  Millions$ 168.462  Millions
Adma Biologics Inc   6.72 $ 273.699  Millions$ 40.715  Millions
Dbv Technologies S a   6.68 $ 169.270  Millions$ 25.325  Millions
Allovir Inc   6.65 $ 220.019  Millions$ 33.066  Millions
Prime Medicine Inc   6.56 $ 184.531  Millions$ 28.147  Millions
Tenaya Therapeutics Inc   6.55 $ 126.828  Millions$ 19.377  Millions
Inhibikase Therapeutics Inc   6.40 $ 17.551  Millions$ 2.742  Millions
Athira Pharma Inc   6.24 $ 178.504  Millions$ 28.622  Millions
Dyadic International Inc  6.24 $ 9.088  Millions$ 1.457  Millions
Fresh Tracks Therapeutics Inc   6.17 $ 13.013  Millions$ 2.108  Millions
Zura Bio Limited  6.15 $ 104.592  Millions$ 17.012  Millions
Finch Therapeutics Group Inc   6.13 $ 29.919  Millions$ 4.879  Millions

Date modified: 2024-01-10T05:56:45+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com